Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L23a pseudogene 53 (RPL23AP53)
- Target
- RPL23AP53
- Molecular classification
- Pseudogene, Non-coding RNA (long non-coding RNA association in some literature)
01
Overview
Ribosomal protein L23a pseudogene 53 (RPL23AP53) is a non-protein-coding pseudogene located on chromosome 8 (reported also within or near the RPL23A locus on chromosome 12 in some sources)[1][4]. Unlike its parent gene, RPL23A, which encodes a component of the large (60S) ribosomal subunit involved in protein synthesis[8], RPL23AP53 does not translate into a functional protein. Recent research shows that its RNA expression levels are differentially regulated in primary and metastatic melanoma, with higher levels potentially associated with better patient survival and altered immune cell infiltration; however, there is no evidence of a direct mechanistic role in disease, and it is not a conventional drug target or receptor[7]. As a pseudogene, RPL23AP53 is primarily of interest as a possible biomarker in cancer biology, rather than a molecular target for therapy[7].
- Other names
- RPL23A_20_869Ribosomal protein L23a pseudogene 53
02
Mechanism of action
Not applicable (no drugs target RPL23AP53; no mechanism of action described)
03
Biological functions
No established protein-coding function (pseudo/non-functional copy)Possible regulatory or biomarker functions in cell proliferation and immune infiltration, as suggested by differential expression studies in melanomaCorrelates with cellular proliferation and immune cell infiltration in cancer tissue
04
Disease associations
Cancer: Differential expression in melanoma, possible biomarker for survival and immune profilingOther: Limited direct disease associations; its parent gene (RPL23A) has been associated with cancers, but RPL23AP53’s direct involvement is not proven
05
Safety considerations
Not applicable for therapeutic targeting (no documented therapeutic use or safety profile)
06
Interacting drugs
None known (no drugs documented to interact directly with RPL23AP53, due to its pseudogene status)
07
Biomarkers
Possible biomarker for survival and immune status in melanomaExpression levels in melanoma correlate with overall survival and immune cell infiltration assessment
Beyond the preview
Go deeper on Ribosomal protein L23a pseudogene 53 (RPL23AP53).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ribosomal protein L23a pseudogene 53 (RPL23AP53).